CGDV: Strong Track Record And Unique Positioning Make It A Buy

The value category has lagged growth for years, yet CGDV bucks this trend with attractive returns. Click here to read why CGDV ETF is a Strong Buy.

Rapid7 Announces Third Quarter 2025 Financial Results

Annualized recurring revenue ("ARR") of $838 million, an increase of 2% year-over-yearTotal revenue of $218 million, up 2% year-over-year; Product subscriptions revenue of $210 million, up 2% year-ove ...
BMJ Open

Protective and risk factors for eating disorders: protocol for a prospective cohort study of children at familial high risk (BLOOM)

Introduction The aetiology of eating disorders (EDs) is complex, involving an interplay of genetic and environmental factors.
BMJ Open

Effectiveness of SMS reminders to increase demand for HPV immunisation: a randomised controlled trial in Georgia

Objective To assess the effects of behaviourally informed short message service (SMS) reminders on demand for human ...

Guggenheim Macro Opportunities Fund Q3 2025 Commentary

Guggenheim Macro Opportunities Fund returned 2.08% in Q3, outperforming its benchmark, the ICE Bank of America 3-Month U.S.
eLife

Acetylation of H3K115 is associated with fragile nucleosomes at CpG island promoters and active regulatory sites

Acetylation of lysine residues in the tail domain of histone H3 is well characterized, but lysine residues in the histone globular domain are also acetylated. Histone modifications in globular domain ...
Santé log

ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance

Raised 2025 total net revenue guidance to $854.0 million to $873.0 million, adjusted non-GAAP EBITDA to $221.0 million to $228.0 million, and adjusted non-GAAP diluted earnings per share of $7.37 to ...